# Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

> **NCT03579446** · EARLY_PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm

## Interventions

- **DRUG:** Hydrocodone
- **DRUG:** Hydromorphone
- **DRUG:** Levorphanol
- **DRUG:** Morphine
- **DRUG:** Oxycodone
- **DRUG:** Oxymorphone
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT03579446
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-29
- **Primary completion:** 2023-06-15
- **Final completion:** 2023-06-15
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579446, "Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03579446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*